|
|
Clinical effect of procalcitoninin guiding antibiotics in patients with severe infection |
XIE Min-chong |
Foshan Shunde Lunjiao Hospital, Guangdong Province, Foshan 528308, China |
|
|
Abstract Objective To investigate the clinical effect of procalcitonin (PCT) in guiding antibiotics in patients with severe infection.Methods A total of 100 patients with severe infections from May 2017 to February 2019 treated in our hospital were selected.According to the random number table method, patients were divided into conventional treatment group and PCT guide group, 50 cases in each group.The conventional treatment was treated with conventional antibiotics treatment, and the PCT guide group was treated with PCT to guide the treatment of antibiotics.The total effective rate of the two groups was compared; the time of infection control, the average time of antibiotic use, the total length of hospital stay, the level of C-reactive protein monitoring before and after treatment, and the white blood cell count, PCT and the incidence of multi-drug resistant infection of the two groups was compared.Results The total effective rate of the PCT guide group was higher than that of the conventional treatment group, and the difference was statistically significant (P<0.05).The time to control the infection, the antibiotic use time, and the total hospital stay of the PCT guide group were shorter than those of the conventional treatment group, the differences were statistically significant (P<0.05).The level of C-reactive protein in the PCT guide group and the white blood cell count,PCT were lower than those in the conventional treatment group, and the differences were statistically significant (P<0.05).The rate of multidrug-resistant infection in the PCT guide group was 2% (1/50), which was lower than that in the conventional treatment group for 18% (9/50), and the difference was statistically significant (P<0.05).Conclusion PCT can guide the treatment of severe infections,it can achieve the desired effect, can effectively shorten the time of antibiotic use, and reduce the incidence of multi-drug resistant infection.
|
|
|
|
|
[1] |
潘国俊,陈淑华.降钙素原指导重症感染患者抗生素应用的临床意义[J].名医,2018,(12):23,25.
|
[2] |
陈付祥.血清降钙素原在儿童重症细菌感染抗生素降阶梯治疗中的指导价值分析[J].名医,2018,(12):65.
|
[3] |
阿卜力克木·阿卜力米提,帕提古丽·麦提库尔班.降钙素原指导重症感染患者抗生素应用的临床意义[J].世界最新医学信息文摘,2018,18(73):148,150.
|
[4] |
冉群英.降钙素原指导重症感染患者抗生素应用的临床意义[J].中国实用医药,2018,13(14):66-67.
|
[5] |
郭焱,李永江,程静,等.降钙素原与C 反应蛋白水平对老年卒中后肺部感染患者抗生素治疗的临床指导意义[J].山西医药杂志,2017,46(19):2300-2303.
|
[6] |
吴婷,谢晋,刘莎.儿童重症细菌感染抗生素降阶梯治疗中血清降钙素原的指导价值[J].医学理论与实践,2017,30(19):2891-2893.
|
[7] |
Guo SY,Zhou Y,Hu QF,et al.Procalcitonin is a marker of gram-Negative bacteremia in patients with sepsis[J].Am J Med Sci,2015,349(6):499-504.
|
[8] |
史未名,高云仙,毛明伟.血清降钙素原水平对重症合并感染患者抗生素使用的指导价值研究[J].吉林医学,2017,38(8):1515-1516.
|
[9] |
于惠淑.降钙素原指导重症监护室脓毒症患者抗生素治疗的临床效果观察[J].中西医结合心血管病电子杂志,2017,5(16):79.
|
[10] |
董俊林.血清降钙素原指导神经内科ICU 重症患者抗感染的临床价值研究[J].中国社区医师,2016,32(21):134,136.
|
[11] |
徐祥.血清降钙素原(降钙素原)的水平指导神经内科ICU 重症患者合并感染时抗生素使用的价值[J].临床医药文献电子杂志,2017,4(4):641.
|
[12] |
杨宗义,韩志礼,张玉.降钙素原指导的抗感染治疗对重症患者抗生素疗程及预后影响的Meta 分析[J].西北国防医学杂志,2016,37(9):581-584.
|
[13] |
Hoeboer SH,van der Geest PJ,Nieboer D,et al.The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis[J].Clin Microbiol Infect,2015,21(5):474-481.
|
[14] |
刘健.降钙素原指导ICU 重症感染抗生素应用的Meta 分析[J].临床合理用药杂志,2017,10(23):122-123.
|
[15] |
Desmard M,Benbara A,Boudinet S,et al.Post-operative kinetics of procalcitonin after lung transplantation[J].J Heart Lung Transplant,2015,34(2):189-194.
|
|
|
|